151 related articles for article (PubMed ID: 11762716)
1. Elevation of serum pro-gastrin-releasing peptide in patients with medullary thyroid carcinoma and small cell lung carcinoma.
Ide A; Ashizawa K; Ishikawa N; Ishii R; Ando T; Abe Y; Sera N; Usa T; Tominaga T; Ejima E; Nakashima M; Ito K; Ito K; Eguchi K
Thyroid; 2001 Nov; 11(11):1055-61. PubMed ID: 11762716
[TBL] [Abstract][Full Text] [Related]
2. Demonstration and diagnostic significance of pro-gastrin-releasing peptide in medullary thyroid carcinoma.
Inaji H; Komoike Y; Motomura K; Higashiyama M; Ohtsuru M; Funai H; Kasugai T; Koyama H
Oncology; 2000 Aug; 59(2):122-5. PubMed ID: 10971170
[TBL] [Abstract][Full Text] [Related]
3. Immunoreactive gastrin-releasing peptide in medullary thyroid carcinoma.
Modigliani E; Casanova S; Chayvialle JA; Bernard C; Franc B; Cohen R; Calmettes C
J Clin Endocrinol Metab; 1990 Oct; 71(4):831-5. PubMed ID: 1976126
[TBL] [Abstract][Full Text] [Related]
4. Serum pro-gastrin-releasing peptide is a useful marker for treatment monitoring and survival in small-cell lung cancer.
Sunaga N; Tsuchiya S; Minato K; Watanabe S; Fueki N; Hoshino H; Makimoto T; Ishihara S; Saito R; Mori M
Oncology; 1999; 57(2):143-8. PubMed ID: 10461062
[TBL] [Abstract][Full Text] [Related]
5. Lack of elevated serum carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma.
Bockhorn M; Frilling A; Rewerk S; Liedke M; Dirsch O; Schmid KW; Broelsch CE
Thyroid; 2004 Jun; 14(6):468-70. PubMed ID: 15242577
[TBL] [Abstract][Full Text] [Related]
6. Pro-gastrin-releasing peptide (Pro-GRP), a tumor marker for small cell lung cancer.
Oremek GM; Sapoutzis N
Anticancer Res; 2003; 23(2A):895-8. PubMed ID: 12820319
[TBL] [Abstract][Full Text] [Related]
7. Normal perioperative serum calcitonin levels in patients with advanced medullary thyroid carcinoma: case report and review of the literature.
Dora JM; Canalli MH; Capp C; Puñales MK; Vieira JG; Maia AL
Thyroid; 2008 Aug; 18(8):895-9. PubMed ID: 18651801
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer.
Okusaka T; Eguchi K; Kasai T; Kurata T; Yamamoto N; Ohe Y; Tamura T; Shinkai T; Saijo N
Clin Cancer Res; 1997 Jan; 3(1):123-7. PubMed ID: 9815547
[TBL] [Abstract][Full Text] [Related]
9. Increased serum concentrations of pro-gastrin-releasing peptide in patients with renal dysfunction.
Kamata K; Uchida M; Takeuchi Y; Takahashi E; Sato N; Miyake Y; Okubo M; Kodama T; Yamaguchi K
Nephrol Dial Transplant; 1996 Jul; 11(7):1267-70. PubMed ID: 8672021
[TBL] [Abstract][Full Text] [Related]
10. [The routine immunohistochemical diagnosis and surgical treatment of medullary carcinoma of the thyroid].
Gavrailov M; Petkov R; Mladenov B; Todorov G; Kŭtev N
Khirurgiia (Sofiia); 1995; 48(2):17-9. PubMed ID: 8531439
[TBL] [Abstract][Full Text] [Related]
11. Calcitonin, calcitonin gene-related peptide, and gastrin-releasing peptide in familial thyroid medullary carcinoma.
Månsson B; Ahrén B; Nobin A; Böttcher G; Sundler F
Surgery; 1990 Feb; 107(2):182-6. PubMed ID: 2300897
[TBL] [Abstract][Full Text] [Related]
12. Ghrelin in human medullary thyroid carcinomas.
Morpurgo PS; Cappiello V; Verga U; Vicentini L; Vaghi I; Lauri E; Nebuloni M; Beck-Peccoz P; Spada A
Clin Endocrinol (Oxf); 2005 Oct; 63(4):437-41. PubMed ID: 16181236
[TBL] [Abstract][Full Text] [Related]
13. Exploring the application value of pro-gastrin-releasing peptide in the clinical diagnosis and surgical treatment of medullary thyroid carcinoma.
Miao Q; Lv X; Luo L; Zhang J; Cai B
Cancer Med; 2023 Oct; 12(19):19576-19582. PubMed ID: 37754747
[TBL] [Abstract][Full Text] [Related]
14. [Usefulness of serum calcitonin, CEA and AFP assays in the early detection of medullary thyroid carcinoma relapse].
Łacka K; Michałek K; Majewski P
Wiad Lek; 2002; 55(7-8):394-403. PubMed ID: 12428567
[TBL] [Abstract][Full Text] [Related]
15. Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen.
Niho S; Nishiwaki Y; Goto K; Ohmatsu H; Matsumoto T; Hojo F; Ohe Y; Kakinuma R; Kodama T
Lung Cancer; 2000 Mar; 27(3):159-67. PubMed ID: 10699689
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of procalcitonin measurement in patients after total thyroidectomy due to medullary thyroid carcinoma.
Bolko P; Manuszewska-Jopek E; Michałek K; Waśko R; Jaskuła M; Sowiński J
Arch Immunol Ther Exp (Warsz); 2003; 51(6):415-9. PubMed ID: 14692663
[TBL] [Abstract][Full Text] [Related]
17. Early changes in carcinoembryonic antigen but not in calcitonin levels are correlated with the progression-free survival in medullary thyroid carcinoma patients treated with cytotoxic chemotherapy.
Hajje G; Borget I; Leboulleux S; Chougnet C; Al Ghuzlan A; Mirghani H; Caramella C; Hartl D; Schlumberger M; Baudin E
Eur J Endocrinol; 2013 Feb; 168(2):113-8. PubMed ID: 23093698
[TBL] [Abstract][Full Text] [Related]
18. [Detection of remnants after removal of medullary thyroid carcinoma].
Zhang J; Dai W; Lian X; Meng X; Hu Y; Bai Y; Li F; Zhang B
Zhonghua Wai Ke Za Zhi; 2000 Jan; 38(1):19-21. PubMed ID: 11831978
[TBL] [Abstract][Full Text] [Related]
19. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC).
Cohen R; Campos JM; Salaün C; Heshmati HM; Kraimps JL; Proye C; Sarfati E; Henry JF; Niccoli-Sire P; Modigliani E
J Clin Endocrinol Metab; 2000 Feb; 85(2):919-22. PubMed ID: 10690910
[TBL] [Abstract][Full Text] [Related]
20. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma.
Pacini F; Fontanelli M; Fugazzola L; Elisei R; Romei C; Di Coscio G; Miccoli P; Pinchera A
J Clin Endocrinol Metab; 1994 Apr; 78(4):826-9. PubMed ID: 8157706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
